查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985838

馬匹保健市場：依產品類型、疾病、給藥途徑及最終用戶分類－2026-2032年全球市場預測

Equine Healthcare Market by Product Type, Disease Indication, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，馬匹保健市場價值將達到 37 億美元，到 2026 年將成長到 39.5 億美元，到 2032 年將達到 59.3 億美元，複合年成長率為 6.97%。

主要市場統計數據
基準年 2025 37億美元
預計年份：2026年 39.5億美元
預測年份 2032 59.3億美元
複合年成長率 (%) 6.97%

一個關於現代馬匹醫療保健優先事項的權威框架，強調預防、綜合診斷和協作臨床創新。

馬匹醫療保健產業正處於一個轉折點，臨床需求、馬主期望和技術能力在此交匯，迫使醫療服務和產品開發的優先事項重新調整。隨著預防和健康維護變得日益重要，人們對能夠早期發現疾病的診斷方法以及支持馬匹長期運動能力和生活品質的治療方法越來越感興趣。因此，從臨床醫生到馬主，相關人員都在重新審視他們的獸醫實踐和籌資策略，以體現一種更積極主動的馬匹健康管理模式。

技術進步、不斷發展的護理服務模式和馬主期望如何融合，重新定義馬匹醫療保健服務和產品創新。

在技​​術成熟、疾病管理方法不斷演進以及相關人員行為轉變的推動下，馬匹醫療保健領域正經歷著一場變革。先進的影像技術和即時診斷技術正在降低診斷的不確定性，並縮短干預時間。同時，穿戴式監測平台能夠持續收集數據，從而支持制定個人化的護理方案。此外，治療方法也日益多樣化，靶向藥物和旨在促進康復和提升運動表現的專用飼料添加劑的出現，為臨床醫生和馬主提供了更多治療選擇。

評估近期貿易政策轉變對營運和供應鏈的影響，這些轉變正在重組整個馬匹醫療保健行業的採購、供應商選擇和物流優先事項。

美國近期關稅調整為整個馬匹醫療保健產業的供應鏈、籌資策略和產品生命週期規劃帶來了複雜影響。進口零件和成品關稅的提高迫使製造商和經銷商重新評估與供應商的關係，盡可能優先考慮在地採購，並調整物流結構以維持獲利能力和供應的連續性。這些調整對醫療設備、診斷試劑和某些藥品的供應、前置作業時間和成本結構產生了重大影響。

將產品類型、最終用戶、疾病適應症和給藥途徑與策略創新和商業化路徑相結合的綜合細分分析。

有效的細分框架能夠識別產品類型、最終用戶、疾病適應症和給藥途徑等創新與需求交匯點，從而為有針對性的開發和商業化提供藍圖。就產品類型而言，其範圍涵蓋醫療設備、診斷試劑、飼料添加劑、藥品和疫苗。在醫療設備領域，機會體現在用於支援持續評估的監測設備、用於治療骨骼和關節疾病的整形外科器械以及用於實現先進治療的外科器械。診斷試劑包括影像方法、臨床檢測和照護現場技術，這些技術能夠幫助臨床醫生在臨床環境中快速做出決策。飼料添加劑屬於礦物質、營養素和維生素組合藥物的範疇，旨在促進整體健康和恢復。藥品包括抗發炎藥、驅蟲藥、抗生素和荷爾蒙。在抗發炎藥物中，皮質類固醇和非類固醇消炎劑(NSAIDs) 兩大類會影響治療方法選擇，而驅蟲藥則包括體外和體內寄生蟲控制藥物。馬匹護理用抗生素分為BETA-內醯胺類、大環內酯類和四環黴素，激素則分為生長促進劑和生殖促效劑。疫苗有去活化疫苗、減毒活病毒疫苗和重組疫苗三種形式，每種疫苗的儲存和使用方法各不相同。

美洲、歐洲、中東、非洲和亞太地區的區域差異和戰略機會為市場進入和研發優先事項提供了重要的見解。

區域趨勢決定了投資、研究重點和應用最為集中的地區，了解這些差異對於決定市場准入和合作夥伴關係至關重要。在美洲，先進的臨床基礎設施、飼主的高度參與以及蓬勃發展的伴侶馬和競技馬文化，正在推動對先進診斷技術、專業治療方法和綜合護理模式的需求。該地區優先考慮循證干預措施，較早採用了遠端監測和遠端保健服務，並支持特定領域的優質化護理。

競爭分析著重於證據生成、供應鏈敏捷性和策略夥伴關係關係，以推動差異化和市場滲透。

馬匹醫療保健領域的競爭格局呈現出多元化的特點，既有成熟的動物用藥品公司，也有專業的醫療設備診斷設備公司、獸藥分銷網路，以及專注於小眾療法和數位化監測的敏捷型Start-Ups。老字型大小企業往往憑藉其規模、監管經驗和廣泛的分銷網路，在多個產品類型中保持市場地位；而專業公司則憑藉深厚的臨床專業知識、針對性的技術平台以及與獸醫的緊密合作展開競爭。新參與企業則透過數位化工具、即時診斷和配方創新，降低使用門檻，提高飼主參與度，進而帶來顛覆性的潛在競爭優勢。

為產業領導者提供切實可行的策略方法，以增強韌性、臨床驗證創新並透過綜合商業性方法加速推廣應用。

產業領導者應優先考慮一系列切實可行的舉措，以平衡短期業務永續營運與長期創新和實證累積。首先，他們應投資於供應鏈透明度和冗餘性，以減輕貿易政策波動和零件短缺對其營運的影響。透過與多家合格供應商建立合作關係並加強物流規劃，企業可以在維持品質標準的同時降低業務中斷的風險。

一個嚴謹、多方面的研究框架，結合了主要相關人員的見解、監管審查和跨領域分析，得出可操作的結論。

本報告的研究融合了多種定性和定量方法，以確保得出可靠且可操作的結論。主要研究包括對獸醫、實驗室技術人員、行業高管和馬主進行結構化訪談，以了解他們對臨床需求、推廣障礙和產品表現的不同觀點。次要研究則包括對同行評審文獻、監管指南、技術標準和公共文件的全面審查，以獲取基於檢驗資訊來源的觀察結果，並分析區域差異。

對臨床檢驗、互通性和強大的營運系統如何決定馬匹醫療保健的未來成功進行綜合分析和展望。

總之，在技術進步、護理模式演變以及馬主和臨床醫生日益成長的期望的推動下，馬匹醫療保健產業正經歷著重大變革。這些因素為那些能夠提供明確臨床價值、易於實踐且擁有穩健供應鏈的解決方案創造了機會。那些能夠將嚴格的臨床檢驗與切實可行的商業化策略相結合，同時又能靈活適應當地法規和運作實際情況的機構，將最終獲得成功。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：馬匹保健市場：依產品類型分類

  • 醫療設備
    • 監測
    • 整形外科
    • 手術器械
  • 診斷藥物
    • 診斷影像
    • 檢查
    • 照護端
  • 飼料添加劑
    • 礦物質補充劑
    • 營養補充品
    • 維生素補充劑
  • 製藥
    • 抗發炎藥
      • 皮質類固醇
      • NSAIDs
    • 驅蟲
      • 體外寄生蟲控制劑
      • 體內寄生蟲控制劑
    • 抗生素
      • BETA-內醯胺
      • 大環內酯類
      • 四環黴素
    • 荷爾蒙
      • 生長
      • 生殖
  • 疫苗
    • 失活
    • 活病毒疫苗
    • 重組

第9章：馬匹保健市場：依疾病指徵分類

  • 消化系統疾病
    • 絞痛
    • 腹瀉
    • 潰瘍
  • 感染疾病
    • 細菌
    • 寄生蟲
    • 病毒性的
  • 肌肉骨骼疾病
    • 關節疾病
    • 整形外科損傷
    • 軟組織損傷
  • 生殖疾病
    • 子宮內膜炎
    • 不孕症
  • 呼吸系統疾病
    • 下呼吸道
    • 上呼吸道

第10章：馬匹保健市場：依給藥途徑分類

  • 吸入
    • 乾粉
    • 霧化
  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服
    • 液體
    • 粉末
    • 藥片
  • 外用
    • 奶油
    • 凝膠
    • 噴

第11章：馬匹保健市場：依最終用戶分類

  • 馬主
    • 養殖場
    • 個人所有者
  • 網路藥房
    • OTC
    • 處方藥
  • 研究機構
    • 私人的
    • 一般的
  • 動物醫院
    • 大型動物醫院
    • 私人診所

第12章：馬匹保健市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：馬匹保健市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：馬匹保健市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國馬匹醫療保健市場

第16章：中國馬匹保健市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bimeda, Inc.
  • Boehringer Ingelheim GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-3F223D52475E

The Equine Healthcare Market was valued at USD 3.70 billion in 2025 and is projected to grow to USD 3.95 billion in 2026, with a CAGR of 6.97%, reaching USD 5.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.70 billion
Estimated Year [2026] USD 3.95 billion
Forecast Year [2032] USD 5.93 billion
CAGR (%) 6.97%

An authoritative framing of contemporary equine healthcare priorities emphasizing prevention, diagnostic integration, and collaborative clinical innovation

The equine healthcare landscape is at an inflection point where clinical imperatives, owner expectations, and technological capabilities converge to reshape priorities across care delivery and product development. Prevention and wellness are increasingly central, with growing emphasis on diagnostics that enable early detection and on therapeutics that support long-term performance and quality of life. As a result, stakeholders from clinicians to owners are adapting practices and procurement strategies to reflect a more proactive model of equine health management.

Transitioning from a reactive model toward preventive care requires new workflows, investments in monitoring and diagnostics, and greater collaboration between veterinary practitioners, research laboratories, and product developers. These shifts are driven by rising expectations for outcomes, the need for evidence-based interventions, and the broader availability of digital tools that permit remote monitoring and data-driven decision-making. Consequently, organizations operating within this space must reconcile traditional clinical approaches with innovations that promise improved detection, targeted therapies, and measurable welfare gains.

Given these dynamics, the opening of any strategic initiative should emphasize alignment across clinical, commercial, and owner constituencies. Clarity of purpose, coupled with pragmatic pathways for piloting and scaling new technologies, will determine which innovations achieve traction. Ultimately, the equine healthcare sector is moving toward a more integrated, data-informed paradigm that rewards collaboration, rigorous validation, and a clear orientation toward long-term animal welfare.

How technological advances, shifting care delivery models, and owner expectations are coalescing to redefine equine healthcare delivery and product innovation

The equine healthcare environment is experiencing transformative shifts driven by technological maturation, evolving disease management philosophies, and changes in stakeholder behavior. Advanced imaging and point-of-care diagnostics are reducing diagnostic uncertainty and shortening time to intervention, while wearable monitoring platforms are enabling continuous data capture that supports individualized care plans. At the same time, therapeutics are diversifying with targeted pharmaceuticals and specialized feed supplements designed to support recovery and performance, thereby broadening treatment pathways available to clinicians and owners alike.

Concurrently, veterinary practices are adapting to new revenue and care models that emphasize telemedicine, remote monitoring, and subscription-based wellness programs. These operational shifts are accompanied by enhanced expectations from owners for transparency, convenience, and measurable outcomes, which in turn accelerate adoption of services that deliver real-time insights and demonstrable benefits. Research laboratories are responding by prioritizing translational studies that validate diagnostic tools and therapeutic regimens, creating a feedback loop between clinical practice and scientific investigation.

Moreover, regulatory thinking and supply chain resilience are influencing product strategies, prompting manufacturers to invest in formulation stability, cold-chain logistics, and simplified administration routes. Taken together, these trends are not isolated; rather, they reinforce one another to create a more interconnected and agile ecosystem where innovations that demonstrate value and ease of use are most likely to scale.

Assessing the operational and supply chain consequences of recent trade policy shifts that are reshaping procurement, sourcing, and logistics priorities across equine healthcare

Recent tariff changes in the United States have introduced a layer of complexity that affects supply chains, sourcing strategies, and product lifecycle planning across the equine healthcare sector. Increased duties on imported components and finished products have prompted manufacturers and distributors to reassess supplier relationships, prioritize local sourcing where feasible, and reconfigure logistics to preserve margin and continuity of supply. These adjustments have practical implications for the availability, lead times, and cost structure of devices, diagnostics, and select pharmaceutical products.

In response, many stakeholders have pursued diversification strategies to mitigate exposure to single-source dependencies. Manufacturers are exploring alternative manufacturing bases and dual-sourcing arrangements, while distributors and large veterinary practices are intensifying inventory planning and safety stock policies to offset lead-time volatility. At the same time, contract manufacturers and domestic suppliers are experiencing increased interest from clients seeking reliable alternatives to cross-border shipments, which reshapes negotiation dynamics and capacity planning within the industry.

Regulatory compliance and labeling requirements have also become more salient in procurement decisions, as products that must transit complex customs regimes can face additional scrutiny and delay. Consequently, procurement teams are allocating more resources to customs expertise and supplier qualification, while research laboratories and clinicians are prioritizing products whose supply chains offer demonstrable resilience. The combined effect is a market that values transparency, redundancy, and flexibility in the face of evolving trade policies.

Comprehensive segmentation analysis mapping product types, end users, disease indications, and administration routes to strategic innovation and commercial pathways

An effective segmentation framework reveals where innovation and demand intersect across product types, end users, disease indications, and routes of administration, providing a roadmap for targeted development and commercialization. When exploring product type, the landscape encompasses devices, diagnostics, feed supplements, pharmaceuticals, and vaccines. Within devices there are opportunities in monitoring devices that support continuous assessment, orthopedic instruments that address bone and joint conditions, and surgical instruments that enable advanced interventions. Diagnostics span imaging modalities, laboratory-based assays, and point-of-care technologies that bring faster decision-making into clinical contexts. Feed supplements divide into mineral, nutritional, and vitamin formulations that support systemic health and recovery. Pharmaceuticals include anti-inflammatories, anti-parasitic agents, antibiotics, and hormones; within anti-inflammatories the categories of corticosteroids and nonsteroidal anti-inflammatory drugs shape therapeutic choice, while anti-parasitic solutions encompass ectoparasiticides and endoparasiticides. Antibiotic classes relevant to equine care include beta lactams, macrolides, and tetracyclines, and hormones are differentiated by growth- versus reproductive-focused agents. Vaccines are offered in inactivated, live attenuated, and recombinant formats, each with distinct storage and administration considerations.

From an end user perspective, the ecosystem includes equine owners, online pharmacies, research laboratories, and veterinary practices. Equine owners are comprised of breeding farms and individual owners who have differing priorities around management scale and investment in preventive care. Online pharmacies operate across over-the-counter and prescription channels, providing convenience and range but requiring careful clinical oversight. Research laboratories are characterized by private and public institutions that drive innovation and validation, whereas veterinary practices range from large animal hospitals with integrated services to private practices focused on personalized care. Disease indication segmentation likewise highlights areas of clinical need and product alignment: digestive disorders such as colic, diarrhea, and ulcers demand rapid diagnostic and supportive care; infectious diseases categorized as bacterial, parasitic, and viral require integrated prevention and treatment strategies; musculoskeletal disorders covering joint disorders, orthopedic injuries, and soft tissue injuries benefit from combined rehabilitative and pharmaceutical approaches; reproductive disorders including endometritis and infertility intersect with both therapeutic and diagnostic solutions; respiratory disorders divided into lower and upper respiratory conditions necessitate specific administration routes and supportive care plans.

Considering route of administration clarifies development and adoption dynamics across inhalation, injectable, oral, and topical options. Inhalation approaches include dry powder delivery and nebulization, both suited for targeted respiratory interventions. Injectable formats encompass intramuscular, intravenous, and subcutaneous routes that influence onset and dosing strategies. Oral delivery consists of liquids, powders, and tablets that prioritize ease of administration for at-home care scenarios. Topical therapies in creams, gels, and sprays enable localized treatment with minimal systemic exposure. By mapping these segmentation dimensions together, developers and clinicians can better prioritize investments and tailor offerings to the specific needs and constraints of each user group and indication.

Regional differentiation and strategic opportunities across the Americas, Europe Middle East and Africa, and Asia Pacific that inform go to market and R D prioritization

Regional dynamics shape where investment, research emphasis, and adoption are most pronounced, and understanding these differences is essential for market entry and partnership decisions. In the Americas, a combination of advanced clinical infrastructure, strong owner engagement, and a thriving companion and performance equine culture drives demand for diagnostic sophistication, specialized therapeutics, and integrated care models. This region prioritizes high-evidence interventions and shows early adoption for remote monitoring and telehealth-enabled services, which supports a premiumization of care in certain segments.

Within the Europe, Middle East & Africa cluster, variability is pronounced across regulatory environments and veterinary practice norms, yet there is consistent momentum toward harmonized standards of care, particularly for infectious disease surveillance and vaccination strategies. Public-private collaboration and strong research networks in parts of this region are facilitating multicenter studies and translational research, while some markets emphasize cost-effective formulations and pragmatic protocols suited to diverse practice settings.

Asia-Pacific presents a mix of rapid clinical modernization, expanding middle-class ownership of performance and leisure horses, and an increasing focus on local manufacturing capability. In this region, demand growth is often accompanied by targeted investments in domestic research and production, and regulatory pathways continue to evolve to accommodate a broader array of diagnostics and therapeutics. Taken together, each geographic cluster offers distinct opportunities and constraints, so prioritizing regional strategies that account for clinical practice patterns, regulatory frameworks, and local supply chain realities will yield the most sustainable outcomes.

An assessment of competitive dynamics emphasizing evidence generation, supply chain agility, and strategic partnerships that drive differentiation and adoption

Competitive dynamics in equine healthcare are defined by a mix of established animal health manufacturers, specialist device and diagnostics firms, veterinary distribution networks, and agile start-ups focused on niche therapeutics or digital monitoring. Established players tend to leverage scale, regulatory experience, and broad distribution to maintain presence across multiple product categories, while specialist firms compete on deep clinical expertise, targeted technology platforms, and close alignment with veterinary practitioners. New entrants bring disruptive potential through digital tools, point-of-care diagnostics, and formulation innovations that lower barriers to use and enhance owner engagement.

Partnerships between device makers and diagnostic developers are increasingly common, enabling integrated solutions that combine monitoring, data analytics, and therapeutic recommendations. Additionally, collaborations between research laboratories and industry are accelerating translational work that validates new interventions under clinical conditions. Distribution channels also matter: online pharmacies and specialized veterinary distributors influence product visibility and access, while large animal hospitals and private practices shape clinical adoption based on real-world performance and ease of integration into care pathways.

Intellectual property, regulatory experience, and manufacturing agility are differentiators that influence competitive positioning. Firms that can demonstrate clinical outcomes, streamline administration, and provide robust support for practitioners will be better positioned to capture preference. Ultimately, company strategies that emphasize evidence generation, supply chain reliability, and tailored commercial engagement are most likely to succeed in a complex and clinically driven market.

Practical strategic initiatives for industry leaders to strengthen resilience, validate innovations clinically, and accelerate adoption through integrated commercial approaches

Industry leaders should prioritize a set of actionable initiatives that balance near-term operational resilience with longer-term innovation and evidence development. First, invest in supply chain transparency and redundancy to mitigate the operational impacts of trade policy shifts and component scarcity. By fostering relationships with multiple qualified suppliers and strengthening logistics planning, organizations can reduce disruption risk while maintaining quality standards.

Second, accelerate clinical validation programs that pair diagnostics with therapeutics to demonstrate real-world outcomes. Rigorous, translational studies that engage veterinary practices and research laboratories will unlock practitioner confidence and facilitate broader adoption. Third, embrace digital integration by deploying monitoring platforms and telemedicine workflows that improve continuity of care and create value through data-driven insights. These tools should be designed for ease of use and seamless integration into existing clinical systems.

Fourth, tailor commercial approaches to end-user segments by recognizing differences between breeding farms and individual owners, and by developing route-of-administration strategies that prioritize adherence and practicality. Fifth, explore strategic alliances that combine complementary strengths across device, diagnostic, and pharmaceutical domains to deliver bundled offerings aligned with clinical pathways. Finally, commit to regulatory and compliance excellence to expedite approvals and ensure consistent market access. Together, these actions provide a pragmatic roadmap for advancing both business resilience and clinical impact.

A rigorous multi-method research framework combining primary stakeholder insights, regulatory review, and cross segmentation analysis to support actionable conclusions

The research underpinning this report synthesizes multiple qualitative and quantitative approaches to ensure robust, actionable findings. Primary research included structured interviews with veterinary practitioners, laboratory scientists, industry executives, and equine owners to capture diverse perspectives on clinical needs, adoption barriers, and product performance. Secondary research involved a careful review of peer-reviewed literature, regulatory guidance, technical standards, and public policy documents to ground observations in validated sources and to contextualize regional differences.

Analytical methods incorporated cross-segmentation mapping to identify where product types, end users, disease indications, and routes of administration intersect with unmet needs. Supply chain and trade policy analyses were conducted using customs data, logistics performance indicators, and public trade notices to assess operational vulnerabilities. Competitive landscape analysis combined patent filings, product registries, and clinical trial registries to evaluate innovation trajectories and differentiation strategies. Throughout the study, methods emphasized triangulation of evidence, iterative validation with subject-matter experts, and sensitivity to regional regulatory and practice variations.

This layered methodology ensures conclusions are grounded in observed practice and documented evidence while remaining sensitive to emerging trends. Where primary data were limited, findings were qualified and cross-checked to preserve analytic integrity, and recommendations were formulated to be pragmatic and implementable across a range of organizational contexts.

Synthesis and forward looking perspective on how clinical validation, interoperability, and resilient operations will determine future success in equine healthcare

In closing, the equine healthcare sector is undergoing meaningful evolution driven by technological advances, shifting care models, and heightened expectations from owners and clinicians. These forces are creating opportunities for solutions that deliver clear clinical value, are easy to integrate into practice, and exhibit resilient supply chains. Success will favor organizations that can marry rigorous clinical validation with pragmatic commercialization strategies, while also demonstrating responsiveness to regional regulatory and operational realities.

Going forward, stakeholders who invest in translational research, prioritize interoperability between diagnostics and therapeutics, and engage owners through user-friendly platforms will secure competitive advantage. Moreover, those who proactively address supply chain and policy risks through diversified sourcing and robust logistics planning will be better equipped to sustain operations in a fluid trade environment. Ultimately, the most impactful advances will emerge from collaborations that bridge research, clinical practice, and product development, producing interventions that meaningfully enhance equine welfare and performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Equine Healthcare Market, by Product Type

  • 8.1. Devices
    • 8.1.1. Monitoring
    • 8.1.2. Orthopedic
    • 8.1.3. Surgical Instruments
  • 8.2. Diagnostics
    • 8.2.1. Imaging
    • 8.2.2. Laboratory
    • 8.2.3. Point Of Care
  • 8.3. Feed Supplements
    • 8.3.1. Mineral Supplements
    • 8.3.2. Nutritional Supplements
    • 8.3.3. Vitamin Supplements
  • 8.4. Pharmaceuticals
    • 8.4.1. Anti-Inflammatories
      • 8.4.1.1. Corticosteroids
      • 8.4.1.2. NSAIDs
    • 8.4.2. Anti-Parasitic
      • 8.4.2.1. Ectoparasiticides
      • 8.4.2.2. Endoparasiticides
    • 8.4.3. Antibiotics
      • 8.4.3.1. Beta Lactams
      • 8.4.3.2. Macrolides
      • 8.4.3.3. Tetracyclines
    • 8.4.4. Hormones
      • 8.4.4.1. Growth
      • 8.4.4.2. Reproductive
  • 8.5. Vaccines
    • 8.5.1. Inactivated
    • 8.5.2. Live Attenuated
    • 8.5.3. Recombinant

9. Equine Healthcare Market, by Disease Indication

  • 9.1. Digestive Disorders
    • 9.1.1. Colic
    • 9.1.2. Diarrhea
    • 9.1.3. Ulcers
  • 9.2. Infectious Diseases
    • 9.2.1. Bacterial
    • 9.2.2. Parasitic
    • 9.2.3. Viral
  • 9.3. Musculoskeletal Disorders
    • 9.3.1. Joint Disorders
    • 9.3.2. Orthopedic Injuries
    • 9.3.3. Soft Tissue Injuries
  • 9.4. Reproductive Disorders
    • 9.4.1. Endometritis
    • 9.4.2. Infertility
  • 9.5. Respiratory Disorders
    • 9.5.1. Lower Respiratory
    • 9.5.2. Upper Respiratory

10. Equine Healthcare Market, by Route Of Administration

  • 10.1. Inhalation
    • 10.1.1. Dry Powder
    • 10.1.2. Nebulization
  • 10.2. Injectable
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Oral
    • 10.3.1. Liquids
    • 10.3.2. Powders
    • 10.3.3. Tablets
  • 10.4. Topical
    • 10.4.1. Creams
    • 10.4.2. Gels
    • 10.4.3. Sprays

11. Equine Healthcare Market, by End User

  • 11.1. Equine Owners
    • 11.1.1. Breeding Farms
    • 11.1.2. Individual Owners
  • 11.2. Online Pharmacies
    • 11.2.1. OTC
    • 11.2.2. Prescription
  • 11.3. Research Laboratories
    • 11.3.1. Private
    • 11.3.2. Public
  • 11.4. Veterinary Practices
    • 11.4.1. Large Animal Hospitals
    • 11.4.2. Private Practices

12. Equine Healthcare Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Equine Healthcare Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Equine Healthcare Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Equine Healthcare Market

16. China Equine Healthcare Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bimeda, Inc.
  • 17.6. Boehringer Ingelheim GmbH
  • 17.7. Ceva Sante Animale S.A.
  • 17.8. Dechra Pharmaceuticals PLC
  • 17.9. Elanco Animal Health Incorporated
  • 17.10. Merck & Co., Inc.
  • 17.11. Norbrook Laboratories Limited
  • 17.12. Vetoquinol S.A.
  • 17.13. Virbac S.A.
  • 17.14. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EQUINE HEALTHCARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EQUINE HEALTHCARE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EQUINE HEALTHCARE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES EQUINE HEALTHCARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA EQUINE HEALTHCARE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EQUINE HEALTHCARE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY JOINT DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY JOINT DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY JOINT DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC INJURIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC INJURIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC INJURIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SOFT TISSUE INJURIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SOFT TISSUE INJURIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SOFT TISSUE INJURIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOMETRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOMETRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOMETRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFERTILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFERTILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFERTILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LOWER RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LOWER RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LOWER RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY UPPER RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY UPPER RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY UPPER RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DRY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DRY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DRY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NEBULIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NEBULIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NEBULIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 260. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 261. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 262. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 263. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 264. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 265. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 267. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 268. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 269. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 270. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 271. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 273. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 274. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 275. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 276. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, 2018-2032 (USD MILLION)
  • TABLE 278. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 280. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, 2018-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 284. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 286. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 288. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 290. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 292. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 294. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 296. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 298. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 300. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 302. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, 2018-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 306. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, 2018-2032 (USD MILLION)
  • TABLE 308. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 312. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 314. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 316. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 318. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 320. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 322. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 324. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 326. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 328. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 330. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY END US